<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946632</url>
  </required_header>
  <id_info>
    <org_study_id>TRIPLE-AXEL-ESR</org_study_id>
    <nct_id>NCT02946632</nct_id>
  </id_info>
  <brief_title>Effectiveness &amp; Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes</brief_title>
  <official_title>Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will assess the efficacy and tolerability of a novel,
      initial triple combination therapy with metformin, saxaglipitin, and dapagliflozin, compared
      to conventional stepwise add-on therapy in drug-naïve patients with recently onset type 2
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADA/EASD guideline recommends sequential treatment approach starting with metformin, and
      adding other classes of anti-diabetic medications if target HbA1c is not achieved. However,
      several clinical studies clearly showed that initial dual or triple combination therapy was
      more favorable in terms of glycemic control.

      A DPP-4 inhibitor saxagliptin increases serum level of GLP-1, and potentiates its action of
      increasing glucose-dependent insulin secretion and lowering glucagon secretion. A SGLT-2
      inhibitor dapagliflozin lowers hyperglycemia via blocking SGLT-2 to increase glucosuria, that
      is, in an insulin-independent manner. Therefore, the mechanism of action of these drugs are
      complimentary to that of metformin, and all of these have a low risk of hypoglycemia and
      weight gain.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who met HbA1c &lt; 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>∙ Proportion of patients who met HbA1c &lt; 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who met HbA1c &lt; 7.0% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body HbA1c from baseline to week 104</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight from baseline to week 104</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure from baseline to week 104</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fat and lean mass from baseline to at 104 weeks</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>AEs/SAEs</measure>
    <time_frame>104 weeks</time_frame>
    <description>hypoglycemia, GI trouble, urinary tract infection, genital infection, volume depletion, panreatitis, severe cutaneous events, hypersensitivity reactions)
Vital signs
Collection of clinical chemistry/haematology parameters</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Triple combination therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stepwise add-on therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were started on metformin 1000mg once daily after screening &amp; assignment
At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triple combination therapy</intervention_name>
    <description>Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg</description>
    <arm_group_label>Triple combination therapy group</arm_group_label>
    <other_name>metformin 1000mg</other_name>
    <other_name>dapagliflozin 10mg</other_name>
    <other_name>saxagliptin 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stepwise add-on therapy</intervention_name>
    <description>metformin -&gt; glimepirde -&gt; sitagliptin</description>
    <arm_group_label>Stepwise add-on therapy group</arm_group_label>
    <other_name>Metformin</other_name>
    <other_name>Glimepiride</other_name>
    <other_name>Sitagliptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Drug-naïve patients with type 2 diabetes by American Diabetes Association criteria

          -  HbA1c ≥ 8%, &lt; 10.5% at screening

          -  Age ≥ 18 years, &lt; 65 years

          -  Body mass index (BMI) ≥ 23 kg/m2, &lt; 35 kg/m2

          -  Estimated GFR (eGFR) ≥ 60 ml/min/1.73m2

        Exclusion Criteria:

          -  Uncontrolled hyperglycemia &gt; 270 mg/dl after an overnight fast

          -  Diabetic ketoacidosis

          -  Type 1 diabetes

          -  Confirmed cardiovascular disease (acute coronary syndrome, stroke, or transient
             ischemic attack) within 3 months of screening

          -  Congestive heart failure (New York Heart Association functional class IV)

          -  severe hepatic dysfunction (serum levels of either AST, ALT, or alkaline phosphatase
             above 3 x upper limit of normal (ULN))

          -  alcohol abuse within the 3 months prior to informed consent that would interfere with
             trial participation or any ongoing condition leading to a decreased compliance to
             study procedures or study drug intake

          -  pregnant women, women with potential of pregnancy not using adequate contraception
             method as evaluated by the investigator, lactating women

          -  use of systemic glucocorticoid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SinGon Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>'Korea University Anam Hospital' in Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SinGon Kim, MD</last_name>
    <phone>010-4191-0958</phone>
    <email>k50367@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996 Jan 1;124(1 Pt 2):90-6.</citation>
    <PMID>8554220</PMID>
  </results_reference>
  <results_reference>
    <citation>Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994 Nov 14;154(21):2473-9.</citation>
    <PMID>7979844</PMID>
  </results_reference>
  <results_reference>
    <citation>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602.</citation>
    <PMID>9742976</PMID>
  </results_reference>
  <results_reference>
    <citation>Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.</citation>
    <PMID>18539917</PMID>
  </results_reference>
  <results_reference>
    <citation>ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.</citation>
    <PMID>18539916</PMID>
  </results_reference>
  <results_reference>
    <citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.</citation>
    <PMID>18784090</PMID>
  </results_reference>
  <results_reference>
    <citation>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Review. Erratum in: Diabetes Care. 2013 Feb;36(2):490.</citation>
    <PMID>22517736</PMID>
  </results_reference>
  <results_reference>
    <citation>Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun;19(3):536-57. doi: 10.4158/EP13176.CS.</citation>
    <PMID>23816937</PMID>
  </results_reference>
  <results_reference>
    <citation>Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773-95. doi: 10.2337/db09-9028.</citation>
    <PMID>19336687</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015 Mar;17(3):268-75. doi: 10.1111/dom.12417. Epub 2015 Jan 7.</citation>
    <PMID>25425451</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015 Mar;38(3):394-402. doi: 10.2337/dc14-2365. Epub 2015 Jan 29. Erratum in: Diabetes Care. 2015 Jun;38(6):1173.</citation>
    <PMID>25633662</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28.</citation>
    <PMID>25352655</PMID>
  </results_reference>
  <results_reference>
    <citation>Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005 Jul 28;48(15):5025-37.</citation>
    <PMID>16033281</PMID>
  </results_reference>
  <results_reference>
    <citation>List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009 Apr;32(4):650-7. doi: 10.2337/dc08-1863. Epub 2008 Dec 29.</citation>
    <PMID>19114612</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Sin Gon Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

